Dyslipidemia after allogeneic hematopoietic stem cell transplantation: Evaluation and management

Blood

Volumn 116, Issue 8, 2010, Pages 1197-1204

  Griffith, Michelle L ^a,b   Savani, Bipin N ^b,c   Boord, Jeffrey B ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Veterans Administration Tennessee Valley Health Care System   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AZATHIOPRINE; BILE ACID SEQUESTRANT; COLESEVELAM; CYCLOSPORIN; CYTOCHROME P450 3A4; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PREDNISONE; RAPAMYCIN; ROSUVASTATIN; SIMVASTATIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CONSTIPATION; DIARRHEA; DIETARY FIBER; DIETARY INTAKE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG METABOLISM; DYSLIPIDEMIA; DYSPEPSIA; FLUSHING; GALLSTONE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; INTRAHEPATIC CHOLESTASIS; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NEPHROTIC SYNDROME; NEPHROTOXICITY; OBESITY; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; PANCREATITIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT INDICATION; WEIGHT GAIN;

EID: 77956496390     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-276576     Document Type: Review

References (54)

1. Thompson BH, Stanford W. Update on using coronary calcium screening by computed tomography to measure risk for coronary heart disease. Int J Cardiovasc Imaging. 2005;21(1):39-53. (Pubitemid 41149229)
2. British Heart Foundation Health Promotion Research Group. Coronary Heart Disease Statistics Fact Sheet 2008/2009. www.bhf.org.uk. London: British Heart Foundation; 2008:1-12.
3. Rosas S, Szapary P, Rader DJ. Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein (a), and lipid abnormalities in renal diseases and following solid organ transplantation. Cardiol Clin. 2003;21(3):377-392.
4. Armenian SH, Bhatia S. Cardiovascular disease after hematopoietic cell transplantation: lessons learned. Haematologica. 2008;93(8):1132-1136.
5. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784-3792. (Pubitemid 350159650)
6. Abou-Mourad YR, Lau BC, Barnett MJ, et al. Long-term outcome after Allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010;45(2):295-302.
7. Tichelli A, Passweg J, Wojcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(8):1203-1210.
8. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110(9):3463-3471. (Pubitemid 350106343)
9. Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1)[suppl 1]:23-32.
10. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109(4):1765-1772. (Pubitemid 46239613)
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(24):3143-3421.
12. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43(1):49-54.
13. Lee SJ, Seaborn T, Mao FJ, et al. Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(4):416-420.
14. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet. 2000;356(9234):993-997.
15. Annaloro C, Usardi P, Airaghi L, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2008;41(9):797-804. (Pubitemid 351696344)
16. Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(9):1100-1107.
17. Copeland EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
18. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G. Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag. 2008;4(4):825-836.
19. Cohen A, Bekassy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008;41[suppl 2]:S43-S48. (Pubitemid 351864707)
20. Turchin A, Wiebe DA, Seely EW, Graham T, Longo W, Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant. 2005;35(1):85-89. (Pubitemid 40090061)
21. Zidan H, Lo S, Wiebe D, Talano J, Alemzadeh R. Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver. Pediatr Blood Cancer. 2008;50(6):1280-1281. (Pubitemid 351555562)
22. Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med. 2007;357(15):1561-1562.
23. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2(9):807-818.
24. White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J. 2006;119(1240):U2125.
25. Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int. 1982;22(1):42-47.
26. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63(3):331-338.
27. Subramanian S, Trence DL. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am. 2007;36(4):891-905. (Pubitemid 350026255)
28. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol. 2008;40(2):521-527.
29. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104(4):984-991.
30. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006;37(3):249-261.
31. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239. (Pubitemid 38924592)
32. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-2251.
33. Bonow RO. Should coronary calcium screening be used in cardiovascular prevention strategies? N Engl J Med. 2009;361(10):990-997.
34. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929-2936. (Pubitemid 43923954)
35. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96(5):1398-1402. (Pubitemid 27375328)
36. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines, revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke. 2000;31(11):2751-2766.
37. Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma [Correspondence]. Bone Marrow Transplant. 2005;36(8):739-740. (Pubitemid 41518722)
38. Hong R, Sequeira W. Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy. J Clin Rheumatol. 2000;6(6):324-327. (Pubitemid 32104202)
39. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4[suppl 7]:13-53. (Pubitemid 38436863)
40. Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J. 2004;148(2):200-210. (Pubitemid 39092785)
41. Butani L. Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Pediatr Transplant. 2005;9(6):746-753. (Pubitemid 41680710)
42. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412-422.
43. Broady R, Levings MK. Graft-versus-host disease: suppression by statins. Nat Med. 2008;14(11):1155-1156.
44. Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588-4598. (Pubitemid 351377828)
45. Arnadottir M, Berg AL. Treatment of hyperlipidemia in renal transplant recipients. Transplantation. 1997;63(3):339-345. (Pubitemid 27086022)
46. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol. 2007;99(6A):47C-55C.
47. Shaw SM, Chaggar P, Ritchie J, et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation. 2009;87(5):771-775.
48. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl. 2009;15(5):504-508.
49. Celik S, Doesch A, Erbel C, et al. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation. 2008;86(2):245-250.
50. Sadovsky R, Kris-Etherton P. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad Med. 2009;121(4):145-153.
51. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-2757. (Pubitemid 35364932)
52. Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel-versus- aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol. 2009;104(8):1052-1054.
53. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15(12):1993-1999.
54. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567-572. (Pubitemid 34833176)